← All trials
NCT06441994
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 24, 2024
- Primary completion
- Mar 31, 2027
- Completion date
- Mar 31, 2027
- First posted
- Jun 4, 2024
- Last posted
- Jul 23, 2024
- Enrollment
- 15
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Osaka UniversityLead sponsor
- Osaka UniversitySponsor investigator
- Japan Agency for Medical Research and DevelopmentCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.